Methylcobalamin
As of the edition of 20 October 2026, Methylcobalamin is a small molecule: marketed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Small molecule
- Brand name
- Methycobal Medilink Pharmaceuticals
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Medilink Pharmaceuticals Ltd.
- Registered trials
- 8, 1 stopped early
- Disease areas
- Mental health; Nervous system; Immune system; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 1 |
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 3 | 3 | 2 | 1 | 0 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Eisai | Lead sponsor of trials | 2017 to now |
| AgelessRx | Lead sponsor of trials | 2025 to now |
| Wanbangde Pharmaceutical | Lead sponsor of trials | 2025 to now |